Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126990231 | 12699023 | 1 | I | 20160826 | 20160830 | 20160830 | PER | US-GLAXOSMITHKLINE-US2016125174 | GLAXOSMITHKLINE | 0.00 | F | Y | 0.00000 | 20160830 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126990231 | 12699023 | 1 | PS | LAMICTAL XR | LAMOTRIGINE | 1 | Oral | 400 MG AM, 450 MG PM | 22115 | PROLONGED-RELEASE TABLET | |||||||||
| 126990231 | 12699023 | 2 | SS | Lamotrigine Tablet | LAMOTRIGINE | 1 | Oral | UNK, BID | Y | 0 | TABLET | BID | |||||||
| 126990231 | 12699023 | 3 | SS | LAMICTAL | LAMOTRIGINE | 1 | UNK, U | Y | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126990231 | 12699023 | 1 | Epilepsy |
| 126990231 | 12699023 | 2 | Epilepsy |
| 126990231 | 12699023 | 3 | Epilepsy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126990231 | 12699023 | OT |
| 126990231 | 12699023 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126990231 | 12699023 | Drug ineffective | |
| 126990231 | 12699023 | Seizure | |
| 126990231 | 12699023 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |